div > div.group > p:first-child"> The IBB biotechnology ETF is on track for its best quarter in six years, adding 19 percent in a rally twice as steep as the gains on the XLV health care ETF.
"For a lot of investors, they're trying to play catch-up at this point in time, and they're going to continue to play these risk assets," Johnson said Friday on CNBC's"Trading Nation.""We still see decent upside from here to go — perhaps about 6 percent higher from here, maybe as high as 13 percent higher.""One of the names that looks pretty good to us is Regeneron," Johnson said.
John Petrides, portfolio manager at Point View Wealth Manager, has a different pick for biotech stock ready to race higher.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »